14TH ANNUAL NATIONAL PHARMACEUTICAL CONGRESS

## OCTOBER 21, 2020 11:00 A.M. - 12:30 P.M.

SESSION 1: CAREER ADVICE IN A POST COVID WORLD SESSION 2: HOW DO WE LAUNCH PRODUCTS POST COVID-19?

# 14th NATIONAL PHARMACEUTICAL CONGRESS

www.pharmacongress.info

#### **Prepared by**

DHIREN MAHIBAN, ASSISTANT EDITOR CHRONICLE COMPANIES

#### Approved by

R. ALLAN RYAN, VICE-PRESIDENT, EDITORIAL DIRECTOR CHRONICLE COMPANIES







When Prescribers want to know more about your brand **NOW**–let a Virtual Voice<sup>®</sup> Rep **impact** them.

**Introducing** the **FIRST** fully encrypted video engagement platform that matches a prescriber with a Virtual Voice<sup>®</sup> rep within minutes or when **THEY** want to be engaged.

## Why Virtual Voice<sup>®</sup> is the ONLY choice.

### Virtual Voice<sup>®</sup> is...

- The ONLY platform offering IMMEDIATE HCP engagement or at THEIR convenience.
- The ONLY platform which houses a library of your brand's video interactions with our Virtual Voice<sup>®</sup> reps.
- The ONLY platform utilizing a proprietary database of fully engaged HCP's.
- The ONLY platform which allows you to BRAND the virtual room to re-enforce awareness.
- The ONLY platform with a broad network of fully trained, GMP compliant professionals with diverse and relevant expertise.

Security and dependability are the corner stones of the Virtual Voice<sup>®</sup> distinct platform. Designed with a 1-click interface there are no passwords, logins or complications, just access to success.

Access is not enough... **IMPACT** changes behavior.

Virtual Voice<sup>®</sup> provides you with the bold reality of your brand in today's environment.

**Virtual Voice**<sup>®</sup> measures and records engagement analytics between Virtual Voice<sup>®</sup> reps and prescribers then houses everything in a library of accessible data, including every call and video interaction.

To learn more, contact James Cran j.cran@vva360.com p: 647.287.9353 www.vva360.com





## Summary

Career advice in a post-Covid world

This report, prepared for the exclusive use of delegates attending the 14th National Pharmaceutical Congress, summarizes industry findings on career advice in a post-Covid-19 world and how to successfully launch products following the pandemic.

While it remains too early to tell which changes that have occurred during Covid-19 will remain in place postpandemic, effective communication in person, via video platform or by phone will certainly be essential, , according to an article by Pharma Field.

As healthcare professionals continue to conduct remote consultations with patients and pharma reps, it is important for sales teams to develop a flexible approach and be able to adapt to each type of interaction, notes <u>Graham Hawthorn</u>, the managing director of Chase, an Edinburgh-based organization specializing in recruitment for the pharmaceutical and healthcare sectors.

According to <u>Andy Anderson</u>, the director of Evolve Selection, a company based in Wakefield, UK specializing in recruitment and outsourcing in the pharmaceutical, life sciences and health care fields, most organizations, in the short-term, are making a shift toward a full virtual engagement model, or a hybrid model of face-to-face and virtual engagements. That means recruiting companies will be looking to assess virtual engagement skillsets of candidates as well as the traditional face-to-face customer skillsets.





PEK



# **NEXT GENERATION** COMMERICAL PARTNER

# **OUR SOLUTIONS**

Impres' bespoke service offerings are flexible and always tailored exactly to the needs of our partners. Investments year after year fuels the innovation behind our leading edge solutions so our partners can enjoy a cost effective competitive advantage.



Reach out to us today to be ready for tomorrow.

info@impres.com

 $\left|\right\rangle$ 

# How do we launch products post-Covid-19?

The market research company Ipsos notes that physical distancing brought on by Covid-19 has dramatically changed the lines of communication between healthcare professionals and pharmaceutical manufacturers.

This reduced engagement presents several obstacles for pharma companies preparing for a product launch. Obstacles include:

- Cancellation of medical conferences and congresses, limiting manufacturers' ability to disseminate information.
- Physicians have also severely limited their availability to sales reps during the pandemic. Ipsos' research shows over one-third (38%) of physicians who were seeing reps prior to the pandemic are currently not seeing any reps.
- Further, Covid-19 has altered the patient load at most practices. Physicians report that they
  are seeing 50 to 70% fewer patient visits and 75% of practices have decided to postpone all
  "non-essential" appointments.
- The focus on coronavirus-related visits has shifted the conversations physicians are having with pharmaceutical manufacturers, requiring a novel value proposition and marketing strategy to break through the challenges presented by Covid-19.

IQVIA has tracked the impact of Covid-19 on the way pharma engages with its customers using its ChannelDynamics audit of healthcare professionals/pharma engagement.

According to an article published on <u>pharmaphorum.com</u> (Sept. 3, 2020), IQVIA's data shows how products will be affected by the impacts of the pandemic on patient journeys, the number of new and switch patients, the regulatory, health technology and market access infrastructure of the pharmaceutical market, and the altered level and type of engagement between pharma and healthcare professionals.

# CANADA'S NEWEST SOURCE FOR VERIFIED HEALTHCARE INFORMATION



Supported by some of the largest healthcare institutions, patient groups, industry researchers, and physicians in Canada, **healthing.ca** offers a compliant space for the Canadian healthcare industry to connect and share trusted content to patients and caregivers.

#### LOOKING TO REACH PATIENTS AND CAREGIVERS COMPLIANTLY IN CANADA? VISIT HEALTHING.CA/ADVERTISE TO LEARN HOW WE CAN HELP



\* Includes A.D.A. H content, new content, and fixeds. Weal Sting cure participation January 1, 2020 - October 76, 2020.



# Physicians report

That they are seeing 50 to 70% fewer patient visits and 75% of practices have decided to postpone all "non-essential" appointments. IQVIA's research suggests companies that launched a product in the first half of 2020 should consider special plans for 'ongoing launch' for these products in 2021 to build their full potential.

- These plans should include:
  - Understanding changes in the patient journey
  - Understanding changes in HCP working practices
     and channel preferences
  - Building an effective real-world evidence base

Data sources include reports from **IQVIA**, a provider of biopharmaceutical development and commercial outsourcing services, articles published online and market research group **Ipsos**.



**Continuing the Life Sciences conversation** 





## **Digitally Expedite Patient Access to Medications**

- Remove barriers leveraging digital capabilities of EMRs (Electronic Medical Records)
- Automate and save physicians' time while supporting your brand



#### EMR Drug Accelerator<sup>®</sup>

Expedite the visibility of your new brand to 90% of physicians by rapidly adding to EMR drug databases with EMR Drug Accelerator<sup>®</sup>.

Delayed addition of new drug (DIN) to EMRs poses a significant barrier to the launch uptake, as over 88% of physicians now use EMRs<sup>\*</sup> for prescribing medications.

- Rapid addition of your new brand to EMRs reaching >90% of physicians
- Ensures physicians can easily search, find, and prescribe your new brand
- Reach parity with competitors<sup>†</sup> for visibility within 3-4 months, which may otherwise take over a year

\* Adapted from Canadian Medical Association Workforce Survey 2019 † Potential advantage versus new competitors

$\sim$
PSP Enrollment Form

#### **EMREACH Smart Forms™**

Precision programming to digitally search and auto-populate PSP Enrollment Forms and Provincial Reimbursement Forms (e.g., Special Authorization Forms) using EMREACH Smart Forms<sup>TM</sup>.

- Available at point-of-care and physicians' fingertips
- Automation enables greater accuracy - reducing back and forth between clinic and PSP provider
- Faster initiation of drug treatment for the patient
- Efficient significant time saver
- Electronic transmission of the completed form
- Reach over 75% of specialists

# EMREACH Clinical Tools

Digitization and EMR integration of physician and patient-focused resources (e.g., disease assessment tools, patient brochures) to support physicians' patient care with EMREACH Clinical Tools.

- Ubiquitous availability at physicians' fingertips
- Option of electronic transmission to the patients
- Broad reach to specialists and primary care physicians
- Electronic dissemination save printing and distribution cost
- Available for both branded and unbranded Clinical Tools



Contact: Bernie Muise bernie.muise@emreach.ca 905-407-1992



289.348.1231




# **Speaker Highlights** Wednesday, October 21, 2020 (11:00 AM) Session 1: Career advice in a post-Covid world


**Tiana DiMichele**, Director, Business Development, Impres Inc., Canada's 'Next Generation' Commercial Partner. She offers a unique perspective, having worked on both the corporate and service partner sides of the industry during her 15 years in pharmaceuticals and biotech.

James Hall, Senior Vice President and General Manager, Covis Pharma Canada. Prior to joining Covis, Jim held senior level commercial roles at several multinational pharmaceutical companies, and has more than 30 years of pharmaceutical industry experience in general management, sales, marketing, market access, operations and business development.

**Arima Ventin**, Executive Director, Market Access, Pricing and Government Relations, Allergan (an AbbVie Company). Arima is strongly committed to the vision that healthcare companies should invest in therapies that fulfill unmet medical needs; engage the community in a positive way; and fill gaps in care in neglected therapeutic areas with a high impact on society.

**Brian Canestraro**, General Manager, Intercept Pharmaceuticals. Brian is responsible for the leadership of Intercept's Canadian Operations. He has over 20 years' experience in the innovative pharmaceutical industry where he has held senior roles across Sales & Marketing, Market Access and General Management.





# Target the right HCPs. Maximize brand awareness.

# Introducing Canada's first and only EMAIL database of engaged, motivated healthcare professionals (HCPs).



Precise targeting.

# Why make Care to Know PRO part of your digital communication plan?

**TARGET** HCPs who are engaged with the industry and want to learn about innovative medications.

**SEGMENT** by specialty, location, brand adoption, and more.

**CONTROL THE CONTENT** with the ability to send everything from branded campaigns to learning programs.



# **Speaker Highlights** Wednesday, October 21, 2020 (11:45 AM) Session 2: How do we launch products post Covid-19?

**Karl Frank,** Divisional Director, Bayshore Specialty Rx. Karl is passionate about supporting patient care and the need to streamline the delivery of healthcare in the community. He has spearheaded the growth of Bayshore Specialty Rx into one of Canada's leading service providers of specialty healthcare.

**Ross Glover,** General Manager at Taiho Pharma Canada Inc. Ross is the leader of the Taiho Pharma Canada Executive Team and oversees the operations for the company in Canada, as well as the expansion into the Mexican pharma market. Ross has more than 30 years' experience in the pharma industry and his team is proud to have delivered two new options for oncology patients in Canada since opening the doors at Taiho in February 2017.

**Pat Forsythe,** General Manager, Eisai Inc. Eisai is a Specialty Pharma company focused on neurology and oncology. The company is also focused on improving patients' lives in epilepsy and other seizure disorders, and breast, thyroid, kidney and liver cancer.

**David Renwick,** Vice President and General Manager, Emergent BioSolutions. Emergent is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats.

For a weekly briefing on topics pertinent to healthcare marketers and executives please get your free subscription to the NPC HealthBiz Weekly newsletter by visiting healthbiz.substack.com.



Contact PEAK to discuss flexible, customized sales and marketing solutions for today's unique environment



# **Inside Sales**

Innovative, cost effective ways to increase sales and drive brand awareness





### **Core Inside Sales and Support Services**



Interactive e-detailing









Pharmacy campaign support



Tele-detailing




Hybrid representatives


### **Contact center partner of choice**

Highly trained inside sales reps working across a broad range of therapy areas.

"Working with Ashfield's Inside sales division over the past two years has been fantastic for my business, cost effective and driven demonstrable ROI. The new contact center is fantastic as well. Big advantage"

Director - Multi-channel Marketing







#### For more information contact:

Dave Cann, Director, Business Development - Ashfield Healthcare Canada, Inc. Call **416 579 2141** or email **Dave.Cann@ashfieldhealthcare.com**